3 ms·
The two trials were unrelated: They were in different stages and testing therapies. But both were testing new cancer treatments. One was testing a treatment for
by paulpauper 3y ago
The two trials were unrelated: They were in different stages and testing therapies. But both were testing new cancer treatments. One was testing a treatment for a blood cancer called acute myeloid leukemia, or AML, and the other was testing a new agent for ovarian cancer.
Deaths in clinical trials are thought to be rare.
how is it rare or unexpected when the cancers have a near certain mortality rate for patients whose illnesses have progressed to the point of needing to enroll in a trial, which is often for terminal patients? We're not talking a clinical trial for hair loss.
- justsomehnguy 3y ago> Mersana said Thursday that the FDA had issued a partial clinical hold after five study participants had fatal bleeding events, a rate that was higher than would have been expected. About 560 people have taken the study drug to date, the company said. Because if you write "0.5% deaths with unexpected circumstances triggered FDA to do what it should do" wouldn't be so clickbaity.